Giovannoni G, Rammohan K, Cook S, et al. Proportions of patients with highly active RMS achieving no evidence of disease activity (NEDA) in response to cladribine tablets in CLARITY. ECTRIMS 217, P1143.
Donanemab (Kisunla) krijgt marketingautorisatie van Europese Commissie voor vroeg-symptomatische Alzheimer
okt 2025 | Dementie